NCT00308893 is a Phase 4 clinical trial of Genetic analysis in Depression, sponsored by University Hospital, Tours.

Who is sponsoring NCT00308893?

NCT00308893 is sponsored by University Hospital, Tours.

What drugs are being tested in NCT00308893?

Interventions in NCT00308893: Genetic analysis.

What condition does NCT00308893 study?

NCT00308893 studies Depression.

Is NCT00308893 still recruiting?

NCT00308893 is currently completed. Last updated 16 December 2025.

Last reviewed 2025-12-16 · How we verify

NCT00308893

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brain Derived Neurotrophic Factor (BDNF) Gene Polymorphism and Response to Antidepressants Treatment in Major Depression

Completed Phase 4 Last updated 16 December 2025

What this trial tests

Phase 4 trial testing Genetic analysis in Depression in 188 participants. Completed in 1 June 2012.

Timeline

1 July 2006

Primary endpoint
1 June 2012

1 June 2012

Quick facts

Lead sponsor	University Hospital, Tours
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	188
Start date	1 July 2006
Primary completion	1 June 2012
Estimated completion	1 June 2012
Sites	1 location across France

Drugs / interventions tested

Genetic analysis

Conditions studied

Depression — all drugs for Depression →

Sponsor

University Hospital, Tours

Who can join

18 and older, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Score on Montgomery and Asberg Depression Rating Scale (MADRS)
Time frame: At 3 weeks and 6 weeks

Sponsor's own description

The main hypothesis is that the therapeutic response and pharmacological resistance to ADs in depressed patients can be associated with a polymorphism for the BDNF gene. The research of allelic forms associated to lesser efficiency or inefficiency of ADs could add to the body of evidence that BDNF mediates the mechanism of action of ADs, and could have important practical implications. We propose to compare in a group of patients with major depression, the allelic variability of the BDNF gene between responders and non-responders after a 3-week period and a 6-week period of SSRI treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Genetic analysis

Trials testing the same drug.

NCT05659017 — Candidate Gene for Hyperferritinemia · unknown
NCT04658381 — Genetic Analysis and Multimodal Retinal Imaging of Asymptomatic Fovea Plana Cases in the General Population · NA · completed
NCT04202185 — Evaluation of a Cohort of Congenital Deep Deafness Patients and/or With Auditory Neuropathy, Looking for DFNB9 · completed
NCT05443113 — Young Pectus Excavatum Patients and Genetic Defects · completed
NCT04507984 — Universal Familial Hypercholesterolemia Screening in Children · completed

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Other University Hospital, Tours trials

Trials by the same sponsor.

NCT07452978 — Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence · Phase 2 · not yet recruiting
NCT07443800 — Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia · NA · not yet recruiting
NCT07251530 — Communication Enhancement Among Ventilated Patients in Intensive Care · not yet recruiting
NCT07189338 — Apneic Oxygenation With High-flow Nasal Oxygenation After Preoxygenation With Noninvasive Ventilation Before Intubation · NA · not yet recruiting
NCT07054112 — Efficacy of Live Online Course Mindfulness Program on Perceived Fatigue in Hemodialysis Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00308893 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Tours
Last refreshed: 16 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00308893.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing